

# Peter Yao

+41 78 902 71 76 • peterjyao@gmail.com  
peterjyao.github.io/vitae/ • peterjyao

## About Me

---

Versatile, data-driven scientist, interested in modelling of manufacturing processes, visualization and analysis, and applying data science in the chemical and biopharmaceutical industries.

## Work Experience

---

### Lonza AG

Basel, Switzerland

*Lead Scientist, Drug Product Services*

*Nov 2020 – Present*

Pharmaceutical development studies for liquid and lyophilized biologic drug products. Laboratory-scale modelling of fill/finish processes.

- Established laboratory study workflow for ambient light photostability evaluations.
- Supported risk assessments for Biologics License Applications (BLA) by Cause and Effect Matrix and Failure Mode and Effects Analysis (FMEA).
- Collaborated with multiple teams to support implementation of early phase programs in clinical supply manufacturing.

### Janssen Pharmaceuticals

Schaffhausen, Switzerland

*Senior Associate Scientist, Large Molecule DP Development*

*Jan 2018 – Oct 2020*

Aseptic fill/finish processes for new drug product introductions and technical transfers at Schaffhausen facility.

- Led development laboratory efforts to identify solutions to technical problems in manufacture of a commercial product and create estimated 1M CHF/year in savings when implemented.
- Implemented laboratory study workflow to evaluate filtration performance and ensure smooth operation of the critical unit operation in aseptic manufacturing.
- Collaborated with multifunctional team to identify and implement new process analytical technologies to verify process models and gain new insights during manufacturing.

### Janssen Pharmaceuticals

Schaffhausen, Switzerland

*Senior Associate Scientist, Small Molecule API Development*

*Nov 2015 – Dec 2017*

Support for late-stage chemical development of small molecule APIs and intermediates. Crystallization process development and process analytical technologies.

- Responsible for development, evaluation of polymorph control, and definition of proven acceptable ranges of key crystallization step in synthetic route for a commercial product.
- Led the study of an enantiomeric resolution by crystallization to establish fundamental system properties and identify key crystal forms.

**Bristol-Myers Squibb****New Brunswick (NJ), USA***Research Scientist, Chemical Development**Jan 2008 – Aug 2013*

Support for early-stage chemical development of small molecule APIs and intermediates. Synthetic route evaluation. Enabling syntheses to deliver clinical material.

- Responsible for development of a process to deliver API for a commercial product with highly specific powder properties suitable for roller compaction and acted as liaison between laboratory development team and pilot plant operations team.
- Worked with a rapidly organised team to deliver clinical material of a highly potent intermediate for an antibody drug conjugate under aggressive timelines.
- Collaborated on diverse multi-functional teams to achieve multiple end-to-end objectives across a variety of projects for six development programs.

## Education

---

**University of Illinois at Urbana-Champaign****Illinois, USA***MS Chemistry**2007*

Main-group asymmetric catalysis

Advisor: Prof. Scott E. Denmark

**Case Western Reserve University****Ohio, USA***BS Chemical Engineering, BS Polymer Science and Engineering**2004*

Advisor: Prof. Christoph Weder

## Qualifications

---

process modelling, process scale-up, statistical analysis, process analytical technologies (PAT), aseptic fill/finish, data visualization, chemical process optimization, R, python

## Languages

---

English : Native - French : B2 - German : B1

## Publications

---

1. Kokil, A., Yao, P., & Weder, C. (2005). Organometallic Networks Based on 2,2'-Bipyridine-Containing Poly(*p*-phenylene ethynylene)s. *Macromolecules*, 38(9), 3800–3807.
2. Denmark, S. E., Eklov, B. M., Yao, P. J., & Eastgate, M. D. (2009). On the Mechanism of Lewis Base Catalyzed Aldol Addition Reactions: Kinetic and Spectroscopic Investigations Using Rapid-Injection NMR. *Journal of the American Chemical Society*, 131(33), 11770–11787.